The Next Step in BTK Efficacy.
XIENCE Prime™ BTK Everolimus Eluting Peripheral Stent System is clinically proven for primary stenting of focal and long lesions and is engineered for outstanding performance.1,2
Advancing BTK efficacy
Clinically Proven
- Excellent long-term patency (angiographic binary in-stent restenosis (>50% stenosis)) of 85.2% and 98.7% limb salvage at 1 year.3,4
Pre-procedure4
Post-procedure4
12 months post-procedure4
Engineered for outstanding performance
- Leading MULTI-LINK stent design for exceptional acute performance, uncompromised radial force, and visibility5
- Coating technology for reliable expansion and controlled Everolimus drug release
- Innovative delivery system for excellent deliverability and confident deployment
Ordering Information
| XIENCE Prime™ BTK Peripheral Stent System | |||||
|---|---|---|---|---|---|
| Stock Number | Stent Diameter (mm) | Stent Length (mm) | Nominbal Pressure (ATM) | RBP (ATM) | Max Stent Expansion Diameter (mm) |
| 1012646-28 | 2.5 | 28 | 8 | 18 | 3.25 |
| 1012646-38 | 2.5 | 38 | 8 | 18 | 3.25 |
| 1012648-28 | 3.0 | 28 | 10 | 18 | 3.75 |
| 1012648-38 | 3.0 | 38 | 10 | 18 | 3.75 |
| 1012649-28 | 3.5 | 28 | 10 | 18 | 4.5 |
| 1012649-38 | 3.5 | 38 | 10 | 18 | 4.5 |
| 1012650-28 | 4.0 | 28 | 10 | 18 | 4.5 |
| 1012650-38 | 4.0 | 38 | 10 | 18 | 4.5 |
References
- Bosiers, M et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease; J Vascular Surgery 2012;55:390-399.
- Bosier, M et al. Outcome of a drug eluted stent in longer below the knee lesions in patients with critical limb ischemia: J Vascular Surgery 2017;58(1):49-54
- M. Bosiers, DESTINY, VEITH 2010
- M. Bosiers, LINC 2011
- Tests and data on file at Abbott
MAT-2115185 v1.0